NCT07074977View on ClinicalTrials.gov

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

January 31, 2027

Conditions
Chronic Pruritus of Unknown Origin
Interventions
DRUG

nemolizumab

Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.

DRUG

Placebo

Participants will receive matching placebo as SC injection.

Trial Locations (3)

35244

Galderma Investigational Site (site# 8893), Birmingham

64506

Galderma Investigational Site (site# 8521), Saint Joseph

94115

Galderma Investigational Site (site# 7075), San Francisco

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY